Skip to content

Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate

Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07573579
Acronym
DYNAMITE-VT
Enrollment
40
Registered
2026-05-07
Start date
2026-08-03
Completion date
2029-08-01
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Tachycardia (VT)

Keywords

Catheter Ablation, Electroanatomical Mapping, Ventricular Tachycardia

Brief summary

Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder and one of the commonest causes of heart-related sudden death. It often affects people who have had a heart attack or other structural heart damage. VT occurs when abnormal electrical circuits develop within and around scar tissue in the heart. People at risk are usually offered an implantable cardiac defibrillator (ICD), a device that can detect VT and deliver a lifesaving shock. While effective, these shocks can be sudden, painful and distressing. Medications such as amiodarone can also help, but they are often unsuitable for long-term use due to their potential side effects on the liver, lungs and thyroid gland. An alternative is catheter ablation. Thin tubes (catheters) are threaded from a blood vessel in the groin to the heart, allowing the cardiologist to identify scar tissue and abnormal electrical circuits, which can be destroyed using heat, freezing or electrical energy. Although ablation can help many patients, VT can return in up to one in three people after the procedure. This is because it can be difficult to precisely identify the scar and surrounding tissue that sustain the abnormal circuits, making it challenging to know exactly where to apply ablation treatment. Dynamic Voltage Mapping, is a technique which the investigators believe can more accurately identify scar and the critical bordering tissue during ablation. Initial data collected suggests that the approach accurately predicts the VT circuit and helps guide ablation. In this study, the investigators wish to recruit 40 participants undergoing VT ablation to determine how effective Dynamic Voltage Mapping is in real-world procedures.

Interventions

PROCEDUREDynamic Voltage Mapping

Dynamic Voltage Mapping uses electrical information collected from catheters positioned within the heart to create an individualised map of the heart, which the investigators hypothesise will better identify scar and surrounding tissue responsible for ventricular tachycardia.

PROCEDUREStandard of Care Ablation

Standard catheter ablation of ventricular tachycardia, guided by operator preference

Sponsors

Liverpool Heart and Chest Hospital NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled for clinically indicated VT ablation (due to sustained VT episodes or ICD therapies). * Willing and able to give informed consent for participation in the trial * Male or female aged between 18-85 * Ischaemic and non-ischaemic cardiomyopathy * ICD insitu

Exclusion criteria

* Unable or unwilling to consent * NYHA Class IV (end stage heart failure) * Metastatic cancer * End stage renal disease * Pregnant or breast feeding * Severe frailty

Design outcomes

Primary

MeasureTime frameDescription
Study FeasibilityFrom enrolment to end of follow up (1 year after procedure)1. Proportion of screened patients who were eligible, approached, consented and recruited 2. Attrition rate: calculated as the total number of recruited patients who withdrew from the study or were lost to follow up 3. Adherence: calculated as the proportion of recruited participants who were able to fully follow the study protocol in both DVM and standard of care arms during their VT ablation procedure.

Secondary

MeasureTime frameDescription
Procedural TimeFrom start of procedure to end (skin-to-skin)Measured in minutes
Ablation time/number of lesionsFrom start of procedure to end (skin-to-skin)Measured by number of ablation lesions applied
Acute VT non-inducibilityFrom start of procedure to end (skin-to-skin)Ability to induce clinical VT at the end of the procedure
VT recurrence RateFrom end of procedure to end of follow up (12 months)Number of sustained VT episodes/ICD shocks/therapies following procedure, recorded by implanted cardiac device

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026